Immunovant, Inc. Board of Directors

Immunovant, Inc., a clinical-stage biopharmaceutical company, develops monoclonal antibodies for the treatment of autoimmune diseases. The company develops batoclimab, a novel fully human monoclonal antibody that target the neonatal fragment crystallizable receptor for the treatment of myasthenia gravis, thyroid eye disease, chronic inflammatory demyelinating polyneuropathy, Graves diseases, and warm autoimmune hemolytic anemia. Immunovant, Inc. is based in New York, New York. Immunovant, Inc. is a subsidiary of Roivant Sciences Ltd.

Ms. Christine Blodgett

Ms. Christine Blodgett

Senior Vice President of Human Resources

Dr. Jay S. Stout Ph.D.

Dr. Jay S. Stout Ph.D.

Chief Technology Officer

Dr. Frank M. Torti M.B.A., M.D.

Dr. Frank M. Torti M.B.A., M.D.

Executive Chairperson of the Board

Ms. Melanie Gloria B.S.N.

Ms. Melanie Gloria B.S.N.

Chief Operating Officer

Mr. Andy Deig

Mr. Andy Deig

Senior Vice President of Strategic Finance

Mr. Christopher A. Van Tuyl Esq., J.D.

Mr. Christopher A. Van Tuyl Esq., J.D.

Chief Legal Officer & Corporate Secretary

Ms. Lauren Schrier M.B.A.

Ms. Lauren Schrier M.B.A.

Vice President of Marketing

Leaving Board of Directors Review Your about to visit the following url Invalid URL

Loading...
Comments


Comment created.